Study of imatinib monotherapy and combination of imatinib with IFN or cytarabine ocfosfate for chronic-phase CML (JALSG CML202 Study)

INTERVENTION: Imatinib Imatinib+Interferon‐alpha Imatinib+Cytarabine ocfosfate CONDITION: Previously untreated chronic‐phase chronic myelogenous leukemia PRIMARY OUTCOME: 1) Imatinib monotherapy: overall survival; 2) Combination therapy: cytogenetic response at 9 months SECONDARY OUTCOME: 1) Imatinib monotherapy: toxicity, hematologic response at 6 months, cytogenetic response at 9 months, progression free survival, time to treatment failure; 2) Combination therapy: toxicity, hematologic response, cytogenetic response, overall survival, progression free survival, time to treatment failure INCLUSION CRITERIA: 1. Chronic phase CML (Ph+ or BCR‐ABL+) previously untreated with IFN 2. Age: 15=< 3. PS 0‐3 (ECOG) 4. No severe organ dysfunction 5. Written informed consent